Dragonfly gets Merck on second TriNKET candidate since 2018 collab; Chinese eye gene therapy developer nabs $60M
Dragonfly Therapeutics is doing better and better in getting Big Pharma on its TriNKET platform. First Celgene, then BMS, and now Merck — again.
After Merck licensed its first candidate from the platform back in November 2020, the pharma giant is back for seconds as part of a 2018 collaboration between the two companies, which was initially focused on a number of solid tumor targets.
The companies expanded their collaboration last year with an agreement to develop and commercialize NK cell engaging immunotherapies for multiple targets in oncology, infectious diseases and immune disorders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
